Kabadi, Udaya M. (2016) Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True! Journal of Diabetes Mellitus, 06 (02). pp. 132-135. ISSN 2160-5831
![[thumbnail of JDM_2016042016123058.pdf]](http://scholar.researcherseuropeans.com/style/images/fileicons/text.png)
Text
JDM_2016042016123058.pdf - Published Version
Download (318kB)
Official URL: https://doi.org/10.4236/jdm.2016.62013
Abstract
It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.
| Item Type: | Article |
|---|---|
| Subjects: | ScienceOpen Library > Medical Science |
| Depositing User: | Managing Editor |
| Date Deposited: | 09 Mar 2023 08:11 |
| Last Modified: | 28 Aug 2024 13:07 |
| URI: | http://scholar.researcherseuropeans.com/id/eprint/716 |
Actions (login required)
- View Item